Tags

Type your tag names separated by a space and hit enter

[Cytokines in bone diseases. Cytokines and malignancy-associated hypercalcemia].
Clin Calcium. 2010 Oct; 20(10):1497-502.CC

Abstract

Malignancy-associated hypercalcemia is one of the commonest causes of hypercalcemia. Clinically, it has been subdivided into HHM (humoral hypercelcemia of malignancy) and LOH (local osteolytic hypercalcemia) . PTHrP (PTH related protein) , which has high homology with PTH in its N-terminus and binds to a common receptor (PTH1R) with PTH, plays a central role in the development of hypercalcemia in HHM. Although most features of HHM can be explained by excessive action of circulating PTHrP, decreased serum level of 1,25 (OH) (2)D and markedly suppressed bone formation found in HHM cannot be explained by the action of N-terminus of PTHrP. Fragments of PTHrP that do not bind to PTH1R, found in the circulation of HHM patients, or some other cytokines secreted by cancer cells may modify the clinical features of HHM. PTHrP also plays important roles in the development of LOH in some cancers, such as breast cancer. In this article, the role of cytokines, mainly PTHrP, in MAH will be reviewed.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Okazaki R
Third Department of Medicine, Teikyo University Chiba Medical Center.

MeSH

HumansHypercalcemiaNeoplasmsParathyroid Hormone-Related ProteinProtein BindingReceptor, Parathyroid Hormone, Type 1

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

20890031

Citation

Okazaki, Ryo. "[Cytokines in Bone Diseases. Cytokines and Malignancy-associated Hypercalcemia]." Clinical Calcium, vol. 20, no. 10, 2010, pp. 1497-502.
Okazaki R. [Cytokines in bone diseases. Cytokines and malignancy-associated hypercalcemia]. Clin Calcium. 2010;20(10):1497-502.
Okazaki, R. (2010). [Cytokines in bone diseases. Cytokines and malignancy-associated hypercalcemia]. Clinical Calcium, 20(10), 1497-502. https://doi.org/CliCa101014971502
Okazaki R. [Cytokines in Bone Diseases. Cytokines and Malignancy-associated Hypercalcemia]. Clin Calcium. 2010;20(10):1497-502. PubMed PMID: 20890031.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cytokines in bone diseases. Cytokines and malignancy-associated hypercalcemia]. A1 - Okazaki,Ryo, PY - 2010/10/5/entrez PY - 2010/10/5/pubmed PY - 2011/2/4/medline SP - 1497 EP - 502 JF - Clinical calcium JO - Clin Calcium VL - 20 IS - 10 N2 - Malignancy-associated hypercalcemia is one of the commonest causes of hypercalcemia. Clinically, it has been subdivided into HHM (humoral hypercelcemia of malignancy) and LOH (local osteolytic hypercalcemia) . PTHrP (PTH related protein) , which has high homology with PTH in its N-terminus and binds to a common receptor (PTH1R) with PTH, plays a central role in the development of hypercalcemia in HHM. Although most features of HHM can be explained by excessive action of circulating PTHrP, decreased serum level of 1,25 (OH) (2)D and markedly suppressed bone formation found in HHM cannot be explained by the action of N-terminus of PTHrP. Fragments of PTHrP that do not bind to PTH1R, found in the circulation of HHM patients, or some other cytokines secreted by cancer cells may modify the clinical features of HHM. PTHrP also plays important roles in the development of LOH in some cancers, such as breast cancer. In this article, the role of cytokines, mainly PTHrP, in MAH will be reviewed. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/20890031/[Cytokines_in_bone_diseases__Cytokines_and_malignancy_associated_hypercalcemia]_ L2 - https://antibodies.cancer.gov/detail/CPTC-PTHrP-1 DB - PRIME DP - Unbound Medicine ER -